In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate

In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate

Some double-blind, placebo-controlled trials have shown that Azelastine (Aze) high dose (0.15%) was effective in seasonal (SAR) and perennial allergic rhinitis (PAR). However, there was no long-term comparison between Aze 0.15% and intranasal corticosteroids (INCS) on safety and quality of life in p...

Full description

Saved in:
Bibliographic Details
Main Authors: Jean Bousquet, MD, Ludger Klimek, MD, Hans-Christian Kuhl, PhD, Duc Tung Nguyen, MD, Rajesh Kumar Ramalingam, MD, G. Walter Canonica, MD, William E. Berger, MD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:World Allergy Organization Journal
Subjects:
Perennial allergic rhinitis
Azelastine
Mometasone furoate
RQLQ
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455124001534
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items